PEGylated Recombinant Adenosine Deaminase Maintains Detoxification and Lymphocyte Counts in Patients with ADA-SCID

Keyphrases

• Recombinant 100%
• Detoxification 100%
• Lymphocyte Count 100%
• PEGylated 100%
• Adenosine Deaminase 100%
• Metabolic Detoxification 50%
• Adenosine Deaminase Activity 50%
• Enzyme Replacement Therapy 20%
• Safety Profile 10%
• Erythrocytes 10%
• Polyethylene Glycol 10%
• Infectious Complications 10%
• 2-dose 10%
• Patient-completed 10%
• Deoxyadenosine 10%
• Safety Outcomes 10%
• Total Hemocyte Count 10%
• Once-weekly 10%
• Injection Pain 10%
• Bioequivalent 10%
• Immune Recovery 10%
• Severe Combined Immunodeficiency 10%
• Well Tolerated 10%
• Efficacy Outcomes 10%
• Weekly Dosing 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Detoxication 100%
• Adenosine Deaminase 100%
• Elapegademase 90%
• Pegademase 63%
• Ethylenediaminetetraacetic Acid 18%
• Enzymes 18%
• Replacement Therapy 18%
• Neutralizing Antibody 9%
• Macrogol 9%
• Deoxyadenosine 9%
• Infectious Complication 9%
• Injection Site Pain 9%
• Severe Combined Immunodeficiency 9%

Immunology and Microbiology

• Lymphocyte Count 100%
• Adenosine Deaminase 100%
• Blood Plasma 18%
• Ethylenediaminetetraacetic Acid 18%
• Neutralizing Antibody 9%
• Immune Reconstitution 9%
• Severe Combined Immunodeficiency 9%
• Erythrocyte 9%
• Polyethylene Glycol 9%